MedCap AB (publ) (FRA:61MA)
Germany
· Delayed Price · Currency is EUR 48.50
-1.45 (-2.90%)
At close: Dec 4, 2025
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2016 - 2020 |
| Sweden Revenue | 914.30M | 898.40M |
Log In |
Log In |
Log In | Upgrade
|
| Nordic (ex-Sweden) Revenue | 567.70M | 448.60M |
Log In |
Log In |
Log In | Upgrade
|
| Europe (ex-Nordic) Revenue | 451.40M | 384.70M |
Log In |
Log In |
Log In | Upgrade
|
| Rest of the World Revenue | 57.80M | 75.10M |
Log In |
Log In |
Log In | Upgrade
|
Revenue Breakdown
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2016 - 2020 |
| Assistive Tech Revenue | 915.60M | 767.20M |
Log In |
Log In |
Log In | Upgrade
|
| Medtech Revenue (Post-Q2 2023 Reporting) | 652.60M | 607.70M |
Log In |
Log In |
Log In | Upgrade
|
| Medtech Revenue (Pre-Q3 2023 Reporting) | 1.57B | 1.37B |
Log In |
Log In |
Log In | Upgrade
|
| Specialty Pharma Revenue | 423.00M | 431.80M |
Log In |
Log In |
Log In | Upgrade
|
Revenue Breakdown 2
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2016 - 2020 |
| Pharmaceuticals Revenue | 413.20M | 420.50M |
Log In |
Log In |
Log In | Upgrade
|
| Assistive Technology Revenue | 915.30M | 765.90M |
Log In |
Log In |
Log In | Upgrade
|
| Medical Devices Revenue | 311.50M | 322.70M |
Log In |
Log In |
Log In | Upgrade
|
| Nutrition & Other Food Revenue | 307.00M | 251.80M |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Revenue | 44.70M | 45.90M |
Log In |
Log In |
Log In | Upgrade
|
Adjusted EBITDA
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2016 - 2020 |
| Assistive Tech Adjusted EBITDA | 250.20M | 212.00M |
Log In |
Log In |
Log In | Upgrade
|
| Medtech Adjusted EBITDA (Post-Q2 2023 Reporting) | 131.80M | 138.30M |
Log In |
Log In |
Log In | Upgrade
|
| Medtech Adjusted EBITDA (Pre-Q3 2023 Reporting) | 382.00M | 350.30M |
Log In |
Log In |
Log In | Upgrade
|
| Specialty Pharma Adjusted EBITDA | 44.50M | 59.20M |
Log In |
Log In |
Log In | Upgrade
|
| Other and Eliminations from Adjusted EBITDA | -24.10M | -21.70M |
Log In |
Log In |
Log In | Upgrade
|
EBIT
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2016 - 2020 |
| Assistive Tech Operating Profit | 186.20M | 164.10M |
Log In |
Log In |
Log In | Upgrade
|
| Medtech Operating Profit (Post-Q2 2023 Reporting) | 89.30M | 98.70M |
Log In |
Log In |
Log In | Upgrade
|
| Medtech Operating Profit (Pre-Q3 2023 Reporting) | 275.50M | 262.80M |
Log In |
Log In |
Log In | Upgrade
|
| Specialty Pharma Operating Profit | 21.20M | 33.40M |
Log In |
Log In |
Log In | Upgrade
|
| Other and Eliminations from Operating Profit | -26.20M | -23.90M |
Log In |
Log In |
Log In | Upgrade
|